Industry Strength Score
1/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
SCIENTURE HOLDINGS INC (SCNX) Stock Price & Overview
NASDAQ:SCNX • US80880X1046
Current stock price
0.4012 USD
+0.01 (+2.61%)
At close:
0.3815 USD
-0.02 (-4.91%)
After Hours:
The current stock price of SCNX is 0.4012 USD. Today SCNX is up by 2.61%. In the past month the price increased by 35.4%. In the past year, price decreased by -57.81%.
SCNX Key Statistics
52-Week Range0.2382 - 2.6
Current SCNX stock price positioned within its 52-week range.
1-Month Range0.2881 - 0.44
Current SCNX stock price positioned within its 1-month range.
- Market Cap
- 16.301M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.80
- Dividend Yield
- N/A
SCNX Stock Performance
Today
+2.61%
1 Week
-2.19%
1 Month
+35.40%
3 Months
-11.69%
Longer-term
6 Months -48.30%
1 Year -57.81%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
SCNX Stock Chart
SCNX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SCNX. When comparing the yearly performance of all stocks, SCNX is a bad performer in the overall market: 91.91% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
SCNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCNX. SCNX has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SCNX Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.11
Revenue Reported
EPS Surprise 61.48%
Revenue Surprise %
SCNX Forecast & Estimates
7 analysts have analysed SCNX and the average price target is 1.53 USD. This implies a price increase of 281.36% is expected in the next year compared to the current price of 0.4012.
For the next year, analysts expect an EPS growth of 77.69% and a revenue growth -21.81% for SCNX
Analysts
Analysts82.86
Price Target1.53 (281.36%)
EPS Next Y77.69%
Revenue Next Year-21.81%
SCNX Financial Highlights
Over the last trailing twelve months SCNX reported a non-GAAP Earnings per Share(EPS) of -4.8. The EPS increased by 37.25% compared to the year before.
Income Statements
Revenue(TTM)11.45M
Net Income(TTM)-20.55M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.61% | ||
| ROE | -24.86% | ||
| Debt/Equity | 0.02 |
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)37.25%
Revenue 1Y (TTM)15.77%
SCNX Ownership
Ownership
Inst Owners3.72%
Shares40.63M
Float31.74M
Ins Owners15.86%
Short Float %5.43%
Short Ratio0.48
SCNX Industry Overview
SCNX operates in the Health Care Technology sub-industry within the Health Care sector. This group contains 31 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
48/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
65%
Outperformed 65% of sub-industries
3 Month Rank
19%
Outperformed 19% of sub-industries
6 Month Rank
1%
Outperformed 1% of sub-industries
Industry Fundamentals & Breadth
- Members
- 31
- New Highs
- 3.2%
- New Lows
- 16.1%
- Average ROE
- 13.6%
- Average Profit Margin
- 24.6%
- Average Operating Margin
- 27.3%
- Average P/E
- 31.8
- Average Fwd P/E
- 21.0
- Average Debt/Equity
- 0.5
SCNX Competitors/Peers
The largest stocks on the US markets in the "Health Care Technology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 19.07 | 28.027B | ||
| DOCS | DOXIMITY INC-CLASS A | 15.08 | 4.614B | ||
| WAY | WAYSTAR HOLDING CORP | 11.25 | 4.016B | ||
| HTFL | HEARTFLOW INC | N/A | 2.459B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 141.59 | 1.166B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.166B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.134B | ||
| CERT | CERTARA INC | 13.45 | 947.579M | ||
| SDGR | SCHRODINGER INC | N/A | 914.754M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.9 | 873.553M | ||
| HSTM | HEALTHSTREAM INC | 27.75 | 607.303M | ||
| PHR | PHREESIA INC | 15.87 | 587.549M | ||
| CTEV | CLARITEV CORP | N/A | 423.062M |
Related stock screener links
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SCNX
Company Profile
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Company Info
IPO: 2020-02-18
SCIENTURE HOLDINGS INC
20 Austin Blvd.
Commack NEW YORK US
Employees: 14
Phone: 18002610281
SCIENTURE HOLDINGS INC / SCNX FAQ
What does SCIENTURE HOLDINGS INC do?
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
What is the current price of SCNX stock?
The current stock price of SCNX is 0.4012 USD. The price increased by 2.61% in the last trading session.
What is the dividend status of SCIENTURE HOLDINGS INC?
SCNX does not pay a dividend.
How is the ChartMill rating for SCIENTURE HOLDINGS INC?
SCNX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is SCIENTURE HOLDINGS INC (SCNX) expected to grow?
The Revenue of SCIENTURE HOLDINGS INC (SCNX) is expected to decline by -21.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for SCIENTURE HOLDINGS INC?
SCIENTURE HOLDINGS INC (SCNX) will report earnings on 2026-05-11.
What is the ownership structure of SCIENTURE HOLDINGS INC (SCNX)?
You can find the ownership structure of SCIENTURE HOLDINGS INC (SCNX) on the Ownership tab.